TANGRAM
LIVE

Serial Number

99240392

Owner

E-THERAPEUTICS PLC

Attorney

Anna King

Filing Date

Jun 18, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TANGRAM Trademark

Serial Number: 99240392

TANGRAM is a trademark filed by E-THERAPEUTICS PLC on June 18, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

E-THERAPEUTICS PLC

4 Kingdom Street
LONDON W2 6BD , GB

Entity Type: 84

TANGRAM THERAPEUTICS PLC

4 KINGDOM STREET
LONDON W2 6BD , GB

Entity Type: 84

Trademark Details

Filing Date

June 18, 2025

Registration Date

Not Registered

Goods & Services

pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation.

Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; pharmaceutical research and development services; drug discovery services; human genetic research; scientific and technical data analysis in the fields of pharmaceuticals, medicines and drug discovery, namely, analysis of pharmaceutical and medical data; design, development, creation and maintenance of computer software platforms and computer software for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; design and development of computer-simulated models; Software as a Service (SaaS) services featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the fields of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the fields of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.

Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid.

Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; recorded and downloadable artificial intelligence and machine learning software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable databases in the fields of pharmaceuticals, medicines and drug discovery; electronic databases for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 10, 2026 ASGN
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 13, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 13, 2026 GNSL
SUSPENSION LETTER WRITTEN
Mar 13, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 11, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 11, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 11, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 12, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 12, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 12, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 6, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 24, 2025 NWOS
NEW APPLICATION ENTERED
Jun 18, 2025 NWAP
APPLICATION FILING RECEIPT MAILED
Jun 18, 2025 MAFR